CDC To Lead Data Accrual On Clinical Validity Of Genetic Tests
This article was originally published in The Gray Sheet
Executive Summary
The Centers for Disease Control and Prevention will establish a public/private consortium to recommend clinical validation and post-marketing data collection processes for predictive genetic disease tests.
You may also be interested in...
Genetic Testing Oversight Public Input Sought By HHS Advisory Panel
HHS' Advisory Committee on Genetic Testing will solicit public input at a Jan. 27 meeting to help determine an appropriate mechanism for the collection and analysis of data on the analytical validity, clinical validity and clinical utility of genetics tests, panel members agreed at their Oct. 26 meeting.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.